SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; hereinafter “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals etc. using 5-aminolevulinic acid (“5-ALA”)(*1) has resolved today at the Board of Directors meeting to succeed its supplement business, a part of the business, by way of absorption-type company split to SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; CEO: Yasushi Takezaki; hereinafter “SBI ALApromo”), setting February 21, 2023 (plan) as the effective date. After this absorption-type company split, SBI ALApromo will be in charge of all the supplement business-related business.

SBI Pharmaceuticals will focus its management resources on pharmaceutical related business, and facilitate strategic business development toward international markets, by collaborating with the pharmaceutical group and companies based in Europe and the United States.

■ Schedule of absorption-type company split

Date of execution of agreement: December 16, 2022

Effective date (plan): February 21, 2023

We appreciate your continued support to the SBI Group’s pharmaceutical and supplement business related to 5-ALA.

(*1) 5-aminolevulinic acid (5-ALA)
An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine, and Asian ginseng. It is also known as a source of chloroplasts in plants.

＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊＊

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.: info_ala@sbigroup.co.jp

Please download PDF version for printing.